Uproleselan's failed Phase III AML trial shakes up GlycoMimetics' future [Yahoo! Finance]
GlycoMimetics, Inc. (GLYC)
Last glycomimetics, inc. earnings: 5/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.glycomimetics.com/investor-relations
Company Research
Source: Yahoo! Finance
survival (OS) of late-line acute myeloid leukaemia (AML) patients in its Phase III, randomised, double-blinded trial (NCT03616470). The efficacy and safety of uproleselan were evaluated in combination with a salvage chemotherapy regimen — mitoxantrone, etoposide and cytarabine (MEC), or fludarabine, idarubicin, and cytarabine (FAI) — given based on the investigators' choice. Patients in the active arm demonstrated a median OS of 13.0 months compared to 12.3 months in the control arm, and statistical significance was therefore not met. No hazard ratio or p-value from the analysis was reported at this stage. Adverse events that occurred were consistent with the known safety profile of the MEC/FAI regimen. In the corporate update call that took place on 6 May, GlycoMimetics stated that it is in discussions with regulatory and statistical experts on further analyses of the comprehensive data set. This is the second discontinuation of a late-stage AML trial in 2024, after Gilead stoppe
Show less
Read more
Impact Snapshot
Event Time:
GLYC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLYC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLYC alerts
High impacting GlycoMimetics, Inc. news events
Weekly update
A roundup of the hottest topics
GLYC
News
- GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- GlycoMimetics, Inc. (NASDAQ: GLYC) was downgraded by analysts at Capital One Financial Co. from an "overweight" rating to an "equal weight" rating.MarketBeat
- GlycoMimetics reports data from Phase III AML treatment trial [Yahoo! Finance]Yahoo! Finance
- We're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024Business Wire
GLYC
Earnings
- 5/9/24 - Miss
GLYC
Analyst Actions
- 3/27/24 - HC Wainwright
GLYC
Sec Filings
- 5/9/24 - Form 10-Q
- 5/8/24 - Form SC
- 5/6/24 - Form 8-K
- GLYC's page on the SEC website